PCI Biotech Holding ASA (PCIB) - Total Liabilities
Based on the latest financial reports, PCI Biotech Holding ASA (PCIB) has total liabilities worth Nkr6.01 Million NOK (≈ $632.21K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PCI Biotech Holding ASA (PCIB) cash flow conversion to assess how effectively this company generates cash.
PCI Biotech Holding ASA - Total Liabilities Trend (2008–2024)
This chart illustrates how PCI Biotech Holding ASA's total liabilities have evolved over time, based on quarterly financial data. Check PCI Biotech Holding ASA liquid asset ratio to evaluate the company's liquid asset resilience ratio.
PCI Biotech Holding ASA Competitors by Total Liabilities
The table below lists competitors of PCI Biotech Holding ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lytus Technologies Holdings PTV. Ltd. Common Shares
NASDAQ:LYT
|
USA | $15.24 Million |
|
Tan Delta Systems PLC
LSE:TAND
|
UK | GBX227.60K |
|
Sejahtera Bintang Abadi Textile Tbk
JK:SBAT
|
Indonesia | Rp495.54 Billion |
|
Groupimo SA
PA:ALIMO
|
France | €1.37 Million |
|
Virpax Pharmaceuticals Inc
NASDAQ:VRPX
|
USA | $2.47 Million |
|
Stayble Therapeutics AB
ST:STABL
|
Sweden | Skr1.44 Million |
|
Baltic Bridge S.A.
WAR:WIS
|
Poland | zł6.36 Million |
|
M Winkworth PLC
LSE:WINK
|
UK | GBX2.79 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down PCI Biotech Holding ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PCI Biotech Holding ASA market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.27 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PCI Biotech Holding ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PCI Biotech Holding ASA (2008–2024)
The table below shows the annual total liabilities of PCI Biotech Holding ASA from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr7.76 Million ≈ $816.79K |
+55.02% |
| 2023-12-31 | Nkr5.01 Million ≈ $526.88K |
-17.63% |
| 2022-12-31 | Nkr6.08 Million ≈ $639.69K |
-72.60% |
| 2021-12-31 | Nkr22.19 Million ≈ $2.33 Million |
+11.61% |
| 2020-12-31 | Nkr19.88 Million ≈ $2.09 Million |
-26.93% |
| 2019-12-31 | Nkr27.20 Million ≈ $2.86 Million |
+59.07% |
| 2018-12-31 | Nkr17.10 Million ≈ $1.80 Million |
+3.06% |
| 2017-12-31 | Nkr16.59 Million ≈ $1.75 Million |
+78.20% |
| 2016-12-31 | Nkr9.31 Million ≈ $979.89K |
-23.14% |
| 2015-12-31 | Nkr12.12 Million ≈ $1.27 Million |
+7.52% |
| 2014-12-31 | Nkr11.27 Million ≈ $1.19 Million |
+20.64% |
| 2013-12-31 | Nkr9.34 Million ≈ $982.84K |
+9.95% |
| 2012-12-31 | Nkr8.49 Million ≈ $893.92K |
+11.31% |
| 2011-12-31 | Nkr7.63 Million ≈ $803.11K |
-16.30% |
| 2010-12-31 | Nkr9.12 Million ≈ $959.48K |
+41.32% |
| 2009-12-31 | Nkr6.45 Million ≈ $678.94K |
+22.31% |
| 2008-12-31 | Nkr5.28 Million ≈ $555.08K |
-- |
About PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more